Sanofi

NASDAQ:SNY

Drug Manufacturers - General

Healthcare
$47.12 -0.73%

-$0.31 today

Market cap
$113.15B
Beta
0.28
P/E (TTM)
8.5
EPS (TTM)
$8.60
Dividend yield
5.62%
52W Low $41.86High $52.68

Volume 2.32M

Average 2.78M

SNY Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

SanofiNASDAQ: SNY

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 75.5%

Gross margin was 75.5% in Q2 FY2026, up 3.3 pp from a year earlier. On a trailing-twelve-month basis it was 73.0%, up 1.4 pp year over year. Over 3 fiscal years it widened by 1.4 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
75.5%+3.4 pp QoQ
Last fiscal yearDec 2025
72.1%+1.9 pp YoY
LTMJun 2026
73.0%+1.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+3.3 pp——
1 year+1.9 pp——
3 years+1.4 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
72.1%
Year-over-year change
+1.9pp

Gross Margin vs competitors

How SNY compares with its peers on the latest reported figures

  • SNY's LTM Jun 2026 gross margin of 73.0% is the 8th highest of the 11 companies compared; the peer median is 74.9%.
  • Its year-over-year change of +1.4 pp is the 2nd highest of 11, against a peer median of +0.3 pp.
  • Over three fiscal years its change of +1.4 pp compares with a peer median of +1.5 pp.
SNY Competitors Peer median
Gross Margin for SNY and competitors
Company Period LTM level YoY 3-year change
LLYEli Lilly and CompanyLTM Jun 202683.4% +0.8 pp+6.3 pp
NVONovo Nordisk A/SLTM Jun 202680.6% -3.3 pp-2.9 pp
AZNAstraZeneca PLCLTM Sep 202680.1% -2.3 pp+9.8 pp
GILDGilead Sciences, Inc.LTM Jun 202679.6% +1.1 pp-0.4 pp
MRKMerck & Co., Inc.LTM Jun 202675.4% -0.1 pp+1.3 pp
NVSNovartis AGLTM Jun 202674.4% -1.8 pp+1.7 pp
PFEPfizer Inc.LTM Jun 202673.2% +1.1 pp+8.3 pp
SNYSanofiLTM Jun 202673.0% +1.4 pp+1.4 pp
GSKGSK plcLTM Jun 202672.7% +1.4 pp+5.0 pp
AMGNAmgen Inc.LTM Jun 202672.7% +8.2 pp-4.9 pp
BMYBristol-Myers Squibb CompanyLTM Jun 202670.2% -0.1 pp-7.0 pp
Peer median (excluding SNY) 74.9%+0.3 pp+1.5 pp

Competitors are the stored peer set for SNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue39.18B40.56B41.62B44.29B46.72B
Cost of Revenue12.26B11.88B12.63B13.21B13.05B
Gross Profit26.92B28.68B28.99B31.08B33.67B
Gross Margin68.7%70.7%69.7%70.2%72.1%
Research & Development5.69B6.5B6.51B7.39B7.84B
Selling, General & Admin9.56B8.74B8.93B9.18B10.24B
Operating Expenses18.79B18.52B22.03B23.83B24.07B
Depreciation & Amortization3.35B3.11B4.43B3.59B5.68B
EBITDA11.54B13.51B11.39B11.03B12.48B
EBITDA Margin29.5%33.3%27.4%24.9%26.7%
Operating Income8.13B10.16B6.96B7.25B9.6B
Operating Margin20.7%25.1%16.7%16.4%20.5%
Interest Income3.13M168.96M530.5M457.53M331M
Interest Expense377.37M384.8M512.82M622.58M626M
Other Income / Expenses(289M)(170M)(845M)(494M)(3.58B)
Income Before Tax7.84B9.99B6.12B6.76B6.02B
Pre-Tax Margin20.0%24.6%14.7%15.3%12.9%
Income Tax Expense1.56B1.91B1.02B1.2B1.04B
Net Income6.22B8.37B5.4B5.56B7.81B
Net Margin15.9%20.6%13.0%12.6%16.7%
EPS (Basic)2.493.192.152.193.20
EPS (Diluted)2.493.182.152.193.20
Weighted Avg Shares2.51B2.5B2.5B2.5B2.44B
Weighted Avg Shares (Diluted)2.51B2.5B2.51B2.5B2.44B

Sanofi

NASDAQ:SNY

Intrinsic Alpha fair value

Locked

Current Price

$47.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.